# A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia

> **NCT06853444** · PHASE1,PHASE2 · RECRUITING · sponsor: **Shanghai Escugen Biotechnology Co., Ltd** · enrollment: 84 (estimated)

## Conditions studied

- Immune Thrombocytopenia (ITP)

## Interventions

- **DRUG:** ESG206
- **DRUG:** ESG206
- **DRUG:** ESG206
- **DRUG:** ESG206

## Key facts

- **NCT ID:** NCT06853444
- **Lead sponsor:** Shanghai Escugen Biotechnology Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-08
- **Primary completion:** 2026-03-31
- **Final completion:** 2027-04-30
- **Target enrollment:** 84 (ESTIMATED)
- **Last updated:** 2025-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06853444

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06853444, "A Phase 1/2 Study of ESG206 in Patients With Primary Immune Thrombocytopenia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06853444. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*